Lisata Therapeutics, Inc. financial data

Symbol
LSTA on Nasdaq
Industry
Pharmaceutical Preparations
Location
110 Allen Road, Second Floor, Basking Ridge, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
Caladrius Biosciences, Inc. (to 9/15/2022), CALADRIUS BIOSCIENCES, INC. (to 9/15/2022), NeoStem, Inc. (to 6/5/2015), PHASE III MEDICAL INC/DE (to 9/1/2006), CORNICHE GROUP INC /DE (to 8/14/2003)
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 805 % -27.7%
Debt-to-equity 14.2 % +39.1%
Return On Equity -55.7 % -46.4%
Return On Assets -48.7 % -41.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.62M shares +3.76%
Common Stock, Shares, Outstanding 8.41M shares +3.18%
Entity Public Float 27.7M USD +10.4%
Common Stock, Value, Issued 8K USD 0%
Weighted Average Number of Shares Outstanding, Basic 8.33M shares +3.17%
Weighted Average Number of Shares Outstanding, Diluted 8.33M shares +3.17%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1M USD
Operating Income (Loss) -22.4M USD +12.8%
Nonoperating Income (Expense) 1.63M USD -35.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -20.8M USD +10.3%
Income Tax Expense (Benefit) -798K USD +65.8%
Net Income (Loss) Attributable to Parent -20M USD +4.1%
Earnings Per Share, Basic -2.4 USD/shares +6.98%
Earnings Per Share, Diluted -2.4 USD/shares +6.98%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 16.2M USD -28.3%
Cash, Cash Equivalents, and Short-term Investments 25.6M USD -42.6%
Accounts Receivable, after Allowance for Credit Loss, Current 900K USD
Assets, Current 34.6M USD -35.9%
Property, Plant and Equipment, Net 72K USD -58.9%
Operating Lease, Right-of-Use Asset 138K USD -55.2%
Intangible Assets, Net (Excluding Goodwill) 400K USD 0%
Other Assets, Noncurrent 160K USD -51.8%
Assets 35M USD -36%
Accounts Payable, Current 1.28M USD -47%
Employee-related Liabilities, Current 2.64M USD -0.94%
Accrued Liabilities, Current 4.33M USD +3.84%
Liabilities, Current 5.61M USD -14.8%
Operating Lease, Liability, Noncurrent 0 USD -100%
Other Liabilities, Noncurrent 72K USD -65.7%
Liabilities 5.69M USD -16.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -81K USD -92.9%
Retained Earnings (Accumulated Deficit) -548M USD -3.78%
Stockholders' Equity Attributable to Parent 29.6M USD -38.6%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 29.3M USD -38.8%
Liabilities and Equity 35M USD -36%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.03M USD +14.3%
Net Cash Provided by (Used in) Financing Activities -142K USD -67.1%
Net Cash Provided by (Used in) Investing Activities 6.44M USD +50.1%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 8.41M shares +3.18%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -788K USD +80.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.2M USD -28.3%
Deferred Tax Assets, Valuation Allowance 27.8M USD +18.2%
Deferred Tax Assets, Gross 27.8M USD +17.9%
Operating Lease, Liability 137K USD -55.1%
Depreciation 29K USD -3.33%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -20M USD +3.98%
Lessee, Operating Lease, Liability, to be Paid 143K USD -57.1%
Property, Plant and Equipment, Gross 661K USD 0%
Operating Lease, Liability, Current 137K USD -18.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 143K USD -24.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 143K USD -24.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6K USD -78.6%
Deferred Tax Assets, Operating Loss Carryforwards 16.1M USD +26.1%
Unrecognized Tax Benefits 344K USD 0%
Additional Paid in Capital 578M USD +0.25%
Amortization of Intangible Assets 71K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 27.8M USD +18.2%
Share-based Payment Arrangement, Expense 1.65M USD -18.9%